Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.
Endocrinology, Diabetes, Metabolism July 16th 2024
MD Newsline
A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.
Oncology, Medical May 20th 2024
Oncology News Central (ONC)
In the evolving landscape of radiation oncology, the discussion around supervision models—direct or virtual—presents a pivotal moment for the field. This debate not only impacts patient access and safety but also stresses upon the profession’s adaptability in integrating technology while preserving core clinical standards.
Oncology, Radiation April 8th 2024
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
Mayo Clinic
In a significant advancement, one physician’s minimally invasive technique for treating membranous urethral strictures post-radiation therapy showcases promising outcomes, including improved urethral patency and reduced operative complications, marking a pivotal shift in patient management strategies.
Urology February 5th 2024
In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.
Oncology, Medical February 5th 2024